FDA Approved: EMPAVELI — Supplemental Application (Apellis Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for EMPAVELI (pegcetacoplan) from Apellis Pharmaceuticals, Inc. to update the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• EMPAVELI (pegcetacoplan)

Snippet

SUPPL AP for EMPAVELI (PEGCETACOPLAN)